The emergence of clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 technology has dramatically advanced how we manipulate the genome. Regarding in vivo experiments, Cas9-transgenic animals could provide efficient and complex genome editing. However, this potential has not been fully realized partly due to a lack of convenient platforms and limited examples of successful disease modeling. Here, we devised two doxycycline (Dox)-inducible Cas9 platforms that efficiently enable conditional genome editing at multiple loci in vitro and in vivo. In these platforms, we took advantage of a site-specific multisegment cloning strategy for rapid and easy integration of multiple single guide (sg)RNAs. We found that a platform containing rtTA at the Rosa26 locus and TRE-Cas9 together with multiple sgRNAs at the Col1a1 locus showed higher efficiency of inducible insertions and deletions (indels) with minimal leaky editing.
Using this platform, we succeeded to model Wilms' tumor and the progression of intestinal adenomas with multiple mutations including an activating mutation with a large genomic deletion. Collectively, the established platform should make complicated disease modeling in the mouse easily attainable, extending the range of in vivo experiments in various biological fields including cancer research.
K E Y W O R D S
complex cancer modeling, CRISPR/Cas9, doxycycline-inducible, in vivo, large genomic deletion Another approach is Cas9-transgenic animals, in which either Cre/ loxP-conditional 6, 7 or Dox-inducible Cas9 8 are used to alleviate the challenges of delivery. Especially in the latter report, sgRNAs were targeted into the genome together with an inducible Cas9 so that the mice were germline-competent with improved mutation efficiency and homogeneity. Nonetheless, the previous inducible Cas9-based platform 8 is suboptimal as a result of the sgRNA loading method, which requires a restriction enzyme-based, one-by-one cloning procedure. In addition, leaky genome editing in vivo has not been fully characterized.
Furthermore, modeling cancer with Cas9-transgenic animals has been mainly demonstrated by combined loss-of-function mutations, which do not fully reflect the genetic diversity found in human cancers.
To make genome editing with Cas9-transgenic animals further accessible, we devised new platforms for efficient genome editing at multiple loci in a Dox-inducible method in vivo. Loading up to four sgRNAs simultaneously into the targeting vector was feasible by using a site-specific multi-segment cloning strategy. 9 A RMCE-10,11 based platform showed efficient genome editing upon Dox administration while displaying minimal levels of unintended insertions and deletions (indels) in the absence of Dox both in vitro and in vivo. Finally, we used this platform to model cancers with complex genome editing including both activating and inactivating mutations in an inducible way. We propose that these platforms can achieve complex genome editing rapidly and efficiently in vivo.
| MATERIAL S AND ME THODS

| Construction of targeting vectors
A prototype of Dox-inducible Cas9 Flp-in vector containing the IRES-mCherry cassette for KH2 ESC was described previously. 12 The Rosa26-tetOP-("Gateway att" site)-IRES-mCherry targeting vector was described previously. 13 Cas9 ORF was cloned from pX330 plasmid (#42230; Addgene, Watertown, MA, USA). To reduce background expression of Cas9, tetOP was replaced with tetracycline response element, third generation (TRE3G, from pTRE3G; Clontech, Mountain View, CA, USA). MultiSite Gateway Cloning Site (MGCS) 9 was cloned upstream of TRE3G by In-Fusion cloning (Clontech).
| Single guide RNAs and rtTA3 cloning by MultiSite Gateway technology
The entire cloning process is represented in Results section and 
| Establishment of Dox-inducible Cas9 ESC
The RMCE-based targeting vector (RC platform) with the desired sgRNAs was electroporated into KH2 ESC using a previously described method. 10 Hygromycin-resistant colonies were selected, expanded and confirmed to be sensitive for G418 Disulfate Aqueous Solution (G418) (Nacalai Tesque, Kyoto, Japan). Homologous recombination-based
Rosa26 targeting vector (R-platform) with the desired sgRNAs (10-20 μg)
was electroporated into V6.5 ESC. Blasticidin-resistant colonies were selected and expanded. The clones were screened by PCR genotyping and confirmed to be positive for mCherry signal with Dox treatment.
| In vitro culture of ESC and mouse embryonic fibroblasts
Cells were maintained at 37°C with 5% CO 2 . ESC were maintained with feeders in ESC culture medium (knockout DMEM containing 2 mmol/L l-glutamine, 1× nonessential amino acids (NEAA) (Nacalai Tesque), 100 U/mL penicillin, 100 μg/mL streptomycin (P/S) (Nacalai Tesque), 15% FBS (Gibco, Gaithersburg, MD, USA), 0.11 mmol/L β-mercaptoethanol (Gibco) and 1000 U/mL human recombinant leukemia inhibitory factor (LIF) (Wako, Osaka, Japan) or without feeders in alternative 2i (a2i) culture medium, which was supplemented with 1.5 μmol/L CGP77675 (Sigma, St Louis, MO, USA) and 3 μmol/L CHIR99021). 15, 16 Mouse embryonic fibroblasts (MEF) were isolated from E15.5 embryos and cultured in DMEM (Nacalai Tesque) with 2 mmol/L l-glutamine, 1× NEAA, P/S, 10% FBS and 0.11 mmol/L β-mercaptoethanol. Immunofluorescence signals were detected by BZ-9000 (Keyence, Osaka, Japan). 
| Green fluorescent protein labeling of ESC
| Animals
All animal studies were conducted in compliance with the ethical regulations of Kyoto University and University of Tokyo, and were approved by the Center for iPS Cell Research and Application (CiRA),
Kyoto University, and the Institute of Medical Science, the University of Tokyo. All mice were maintained in a specific pathogen-free facility. C57BL/6, ICR and pseudopregnant ICR mice were purchased from Japan SLC. Midday on the day when the plug was observed was designated as embryonic day (E) 0.5.
| Chimera formation
Female ICR mice were treated with pregnant mare serum gonadotropin (PMSG; 7.5 IU) and human chorionic gonadotropin (hCG; 7.5 IU) by i.p. injection. Embryos were rinsed with M2 medium (Sigma) and cultured in KSOM medium until development into blastocysts. ESC were tested for Mycoplasma contamination before blastocyst injection. Two to seven cells per embryo were injected into the blastocoels of E3.5 blastocysts. Injected blastocysts were transferred into the uteri of pseudopregnant ICR mice. 
| Doxycycline treatment
| Hematoxylin-eosin staining, immunohistochemistry and immunofluorescence
Samples were fixed with 4% paraformaldehyde overnight at 4°C
and embedded in paraffin using Spin Tissue Processor STP120-2 
| Flow cytometry
Small intestine and thymus were incubated in 1% collagenase type 
| Quantitative RT-PCR
Quantitative PCR was carried out using GoTaq qPCR Mater Mix and CXR Reference Dye according to the supplier's instruction (Promega).
StepOnePlus Real-Time PCR system (Applied Biosystems) was used.
Transcript levels were normalized by β-actin. Experiments were carried out in triplicate. Primers used are shown in Table S1 .
| RE SULTS
| Platforms for Dox-inducible genome editing at multiple loci
We Figure 1C . Briefly, desired sgRNAs were first prepared in template expression plasmids such as pX330. 19 Next, sequences for RNA polymerase III promoter (eg, U6), sgRNA and TTTTTT poly-T (pT) termination were subcloned into pDONR vectors by PCR with specific primers for the BP reaction (Table S1 ) to generate entry clones. Finally, the prepared entry clones were simultaneously recombined by the LR reaction with the targeting vectors for either the RC platform or the R platform.
Alternatively, sequences for the U6 promoter, sgRNA and pT were PCR-amplified from the pX330 template plasmid by long primers that contain the attL or attR site (Table S1) , and were directly applied to the LR reaction. Both BP and LR reactions were highly efficient throughout the study, requiring only 5 to 7 days to prepare targeting vectors ( Figure 1D ). Although RMCE at the Col1a1 locus was efficient, we detected the unrecombined fragment of the targeting vector in one out of nine RC-ES cell lines (data not shown), suggesting that random integrations infrequently occur in this system. Furthermore, indels at the Cdh1 locus were detectable in up to 20%
of alleles even without Dox exposure ( Figure 2E ). These data indi-
cate that the R platform shows leaky and less efficient genome editing than the RC platform in vitro.
| Minimal indels without Dox in RC-ES cells
As previously reported, the simultaneous loading of constitutively expressed sgRNAs and an inducible Cas9 risk unintended mutations before giving Dox. Figure S1B and Figure 2H ). We also confirmed the efficient induction of genome editing even after four passages in RC-ES cells ( Figure 2G ,H). These data showed that the RC platform generates minimal indels in the absence of Dox, whereas the R platform displays significant leaky genome editing even without Dox treatment. As the existence of indels at baseline hinders conditional genome editing in vivo, we used the RC platform for all subsequent experiments.
| Doxycycline-inducible genome editing at multiple loci in somatic cells both in vitro and in vivo
To further examine the applicability of the RC platform in somatic cells, the established RC-ES cells were used directly for RC platform (sgEGFP/Cdh1/Lmna)
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Consistent with efficient genome editing in RC-ES cells, a high
frequency of indels at all three loci was induced in RC-MEF 72 hours after Dox treatment ( Figure 3A and Figure S2A) . A small extent of indels was also observed in RC-MEF without Dox treatment, suggesting that leaky editing occurs in RC-MEF at low frequencies ( Figure 3A ).
F I G U R E 2 Doxycycline (Dox)-inducible genome editing at multiple loci in ES cells. A, Schematic representation of the alleles in the RC and R platforms used in B-E. Both platforms contain an enhanced green fluorescent protein (EGFP)-expressing allele together with three single guide (sg)RNAs targeting EGFP, Cdh1 and Lmna. B, Bright field and immunofluorescence images of embryonic stem cells (ESC) with the RC and R platforms (RC-ES cells and R-ES cells, respectively). Representative images of three independent ESC clones at p3 are shown. Scale bars, 300 μm. C, Flow cytometric analysis of Dox-treated RC-ES and R-ES cells. Representative dot plots of three independent ES cell clones at passage 3 are shown. D, Ratio of the EGFP high population in (C) (red rectangle). E, Kinetics of insertions and deletions (indel) frequencies
at the Cdh1 and Lmna loci. For indel patterns, see also Figure S1A . elements) can be observed in the kidney tumor. Scale bar, 100 μm. F, Six2 immunostaining of the kidney tumor. Scale bar, 100 μm. G, PCR analysis to examine the deletion of Ctnnb1 exon 3 and indels at the Wt1 gene. Primers used (a and b) are indicated in (A). Non-chimeric littermates were used as control. H, Sanger sequencing of genomic DNA at Ctnnb1 exon3 cloned from the PCR product of small intestine (**) in (G). Eight subcloned genomic DNAs per tissue were analyzed (the rest of the sequencing results are shown in Figure S3C ). The sequence between two guide RNAs is removed and shown as a reference 
F, Schematic representation of the alleles in the RC and R platforms used in (G) and (H). RC-and R-ES cells were EGFP-labeled by piggyBac (PB) transposition and
| Modeling Wilms' tumor with Ctnnb1 exon 3 deletion and indels at Wt1 gene
To test whether the RC platform is practical for modeling cancer with complex genomic abnormalities, we first tried to recapitulate a previously reported Wilms' tumor model with the activating mutation at Ctnnb1 in conjunction with the inactivating mutation at Wt1. 21 In the previous study, Ctnnb1 exon 3 was deleted by the conventional Cre/ loxP system, which led to accumulation of the dominant stable form of β-catenin protein. 22, 23 In our strategy, we designed two sgRNAs that flank exon 3 of Ctnnb1 instead of two loxP sites, and one sgRNA to target exon 2 of Wt1 ( Figure 5A ,B). Giving Dox starting at embryonic day 14.5-18.5 (E14.5-18.5) resulted in the growth retardation phenotype in Dox-treated RC-mice ( Figure 5C ). We also observed the development of kidney tumors and dilatation of the intestinal tract ( Figure 5C ).
Notably, histological analysis showed that the kidney tumors had typical features of Wilms' tumor, which include blastemal, stromal, and epithelial components ( Figure 5D ,E). Among the analyzed mice (50% to 70% coat color chimerism in both cohorts), all of three Dox-treated mice showed both kidney and intestinal lesions whereas none of five two previously reported sgRNAs to delete the H19 ICR locus, 26 which spans more than 13 kb, in addition to one sgRNA to target exon 16 of Apc to model the progression of intestinal tumorigenesis ( Figure 6A ).
After giving Dox in vitro, genomic deletions at H19 ICR and indels at Apc were efficiently generated in RC-ES cells ( Figure 6B ,C). We found that the H19 ICR locus was precisely removed between the two sgRNA-targeted sites ( Figure 6D ) and the concomitant upregulation of
Igf2 expression was detectable in Dox-treated RC-ES cells ( Figure 6E ).
RC-mice showed adenomatous lesions in the intestine after 1 week of Dox treatment ( Figure 6F ). Importantly, we confirmed that Dox treatment successfully induced a large deletion at the H19-ICR locus in vivo ( Figure S4A,B) . Moreover, histological analysis showed that adenomatous lesions in RC-mice targeting both the H19 ICR and Apc gene showed higher frequency of mitotic counts when compared with single mutant mice for the Apc gene ( Figure 6F ,G and Figure S4C ). Taken together, complex mutations including a large genomic deletion are efficiently inducible in somatic cells in vivo with the RC platform.
| D ISCUSS I ON
A Dox-inducible Cas9-based RC platform, which has rtTA at the Rosa26 locus and TRE-Cas9 allele together with multiple sgRNAs at the Col1a1 locus, successfully achieved efficient genome editing at multiple loci for complex cancer modeling with much less labor than conventional methods. MultiSite Gateway technology allowed us to combine up to four sgRNAs simultaneously and, therefore, the entire vector construction could be finished within a week, providing a more flexible system than the previously reported platform. 8 Application of the Golden Gate cloning-based system 27 may be useful to further increase the number of targeting loci for genome editing.
It is noteworthy that the R platform, which contains all transgenic components in one construct at the Rosa26 locus, showed significant frequency of leaky indels in the absence of Dox exposure, and showed little improvement in genome editing in response to Dox treatment. These findings suggested that the targeted loci for the Dox-inducible components were important in order to tightly control conditional genome editing with an inducible Cas9 system. Positioning of rtTA and TRE in the inverse direction 28 or using an inducible sgRNA expression system 29 might be useful for rigorous control of genome editing with an inducible Cas9 system.
Finally, we succeeded in modeling cancers with complex genetic abnormalities in an inducible method, including the induction of a large genomic deletion ranging over 13 kb. Efficiencies of the genomic deletion were high enough for mutated alleles to be dominant, indicating that our platform could substitute conventional recombinase-based methods such as Cre/loxP in some cases.
Although it should be noted that the induced mutation patterns were heterogeneous and included in-frame shift mutations, recent reports suggested that the frequency of out-of-frame shift mutations could be increased by selecting a target site flanked by microhomology, resulting in efficient gene knockout.
30,31
Recently, various genomic modifications with CRISPR/Cas9 technology have been reported, including genomic translocation, 32, 33 inversion, chromosome elimination, 34, 35 single point mutation and knock-in. 36 Combining these genome-editing technologies with the RC platform will further facilitate diverse cancer modeling and functional assays in vivo, which should deepen our understanding of the mechanisms that govern various biological phenomena in mammals in vivo.
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